Start: April 19, 2019
End: April 30, 2023
What Is This Study About?
This study will test the safety and feasibility of light and sound stimulation in adults with mild Alzheimer's disease. Researchers are investigating the noninvasive method of stimulating brain waves as a potential way to slow or stop the disease.
Do I Qualify To Participate in This Study?
- Mild Alzheimer's disease (Mini-Mental State Examination score of 19 to 26)
- Able to sign informed consent or legally authorized representative who can provide consent
Must NOT have:
- No health care
- History of seizure, epilepsy, or stroke within past 2 years
- Significant suicide risk and/or suicide attempt in past year
- Behavioral problems such as aggression, agitation, or impulsivity
- Diagnosed with migraine headaches
- Prohibited medications: antiepileptic agents, psychiatric agents (e.g., antidepressants, antipsychotics), N-methyl-D-aspartate receptor antagonists (e.g., memantine), and medications that lower seizure threshold (e.g., bupropion, ciprofloxacin, levofloxacin)
- Active implanted medical device, including cardioverter defibrillator, deep brain stimulator, cardiac pacemaker, or sacral nerve stimulator
- Significant hearing or visual impairment
- Life expectancy less than 2 years
If I Qualify, Who Do I Contact?
Contact study personnel listed either under the general study contact or the location nearest you.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Where Is This Study Located?
Lead: Massachusetts Institute of Technology
Source: ClinicalTrials.gov ID: NCT04042922